Levodopa-induced dyskinesia is a major complication of long-term dopamine replacement therapy for Parkinson’s disease that becomes increasingly problematic in advanced Parkinson’s disease. Although the cause of levodopa-induced dyskinesias is still unclear, recent work in animal models of the corticostriatal system has suggested that levodopa-induced dyskinesias might result from abnormal control of synaptic plasticity. In the present study, we aimed to explore control of plasticity in patients with Parkinson’s disease with and without levodopa-induced dyskinesias by taking advantage of a newly developed protocol that tests depotentiation of pre-existing long-term potentiation-like synaptic facilitation. Long-term potentiation-like plastici...
Repetitive stimulation of the corticostriatal pathway can cause either a long-lasting increase, or a...
Levodopa-induced dyskinesias are disabling motor complications of long-term dopamine replacement in ...
Long-term treatment with the dopamine precursor levodopa (L-DOPA) induces dyskinesia in Parkinson's ...
Loss of dopamine, a key modulator of synaptic signalling, and subsequent pulsatile non-physiological...
Parkinson’s disease (PD) is a neurodegenerative disease, in which the progressive loss of dopamine n...
Parkinson‘s disease (PD) is a progressive and disabling neurodegenerative disease, characterized by ...
Introduction: Chronic dopamine replacement therapies in Parkinson's disease can induce side effects,...
Long-term levodopa (l-dopa) treatment in patients with Parkinson´s disease (PD) is associated with t...
Levodopa-induced dyskinesias are a common and disabling side effect of dopaminergic therapy in Parki...
Maladaptive plasticity can be defined as behavioral loss or even development of disease symptoms res...
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by a loss of dopamine...
Background: The relationship between abnormal cortical plasticity and parkinsonian symptoms remains ...
BACKGROUND: Aberrant plasticity is closely linked to the development of levodopa-induced dyskinesia ...
Objective: Depotentiation of homosynaptic plasticity of the primary motor cortex (M1) is impaired in...
Repetitive stimulation of the corticostriatal pathway can cause either a long-lasting increase, or a...
Levodopa-induced dyskinesias are disabling motor complications of long-term dopamine replacement in ...
Long-term treatment with the dopamine precursor levodopa (L-DOPA) induces dyskinesia in Parkinson's ...
Loss of dopamine, a key modulator of synaptic signalling, and subsequent pulsatile non-physiological...
Parkinson’s disease (PD) is a neurodegenerative disease, in which the progressive loss of dopamine n...
Parkinson‘s disease (PD) is a progressive and disabling neurodegenerative disease, characterized by ...
Introduction: Chronic dopamine replacement therapies in Parkinson's disease can induce side effects,...
Long-term levodopa (l-dopa) treatment in patients with Parkinson´s disease (PD) is associated with t...
Levodopa-induced dyskinesias are a common and disabling side effect of dopaminergic therapy in Parki...
Maladaptive plasticity can be defined as behavioral loss or even development of disease symptoms res...
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by a loss of dopamine...
Background: The relationship between abnormal cortical plasticity and parkinsonian symptoms remains ...
BACKGROUND: Aberrant plasticity is closely linked to the development of levodopa-induced dyskinesia ...
Objective: Depotentiation of homosynaptic plasticity of the primary motor cortex (M1) is impaired in...
Repetitive stimulation of the corticostriatal pathway can cause either a long-lasting increase, or a...
Levodopa-induced dyskinesias are disabling motor complications of long-term dopamine replacement in ...
Long-term treatment with the dopamine precursor levodopa (L-DOPA) induces dyskinesia in Parkinson's ...